Lawrence Steinman insider trades
Open-market stock purchases and sales by Lawrence Steinman, Director at Pasithea Therapeutics Corp, from SEC Form 4 filings since Jun 24, 2019.
Track record: 50% of 2 scored buys are up 5% or more since purchase, averaging +7%.